Assembly Biosciences (ASMB) Net Cash Flow (2010 - 2026)

Assembly Biosciences' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$27.3 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 83.04% year-over-year to -$27.3 million; the TTM figure through Mar 2026 stood at $7.7 million (up 65.24% YoY), while the FY2025 annual figure was $20.1 million, up 8.66% from the prior year.
• Net Cash Flow was -$27.3 million for Q1 2026 at Assembly Biosciences, down from $35.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $35.9 million in Q4 2025 to a low of -$27.3 million in Q1 2026.
• Historically, Net Cash Flow has averaged -$853352.9 across 5 years, with a median of -$1.1 million in 2024.
• Biggest YoY gain for Net Cash Flow was 263.08% in 2025; the steepest drop was 1267.31% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$2.3 million in 2022, then tumbled by 202.22% to -$6.8 million in 2023, then soared by 245.15% to $9.9 million in 2024, then soared by 263.08% to $35.9 million in 2025, then sank by 176.09% to -$27.3 million in 2026.
• The last three Net Cash Flow figures came in at -$27.3 million (Q1 2026), $35.9 million (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.